Search

Your search keyword '"Joshi, Mukta"' showing total 109 results

Search Constraints

Start Over You searched for: Author "Joshi, Mukta" Remove constraint Author: "Joshi, Mukta"
109 results on '"Joshi, Mukta"'

Search Results

3. On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).

5. Heuristics on Call: The Impact of Mobile-Phone-Based Business-Management Advice.

8. Patterns of speciation in a parapatric pair of Saturnia moths as revealed by target capture.

11. Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

12. Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B

14. Neurological Applications

16. Delimiting continuity: Comparison of target enrichment and double digest restriction‐site associated DNA sequencing for delineating admixing parapatric Melitaea butterflies

17. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.

18. Leveraging Behavioral Science to Increase the Impact of Economic Inclusion Programming

19. Delimiting continuity: Comparison of target enrichment and double digest restriction-site associated DNA sequencing for delineating admixing parapatric Melitaea butterflies

21. Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

22. Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study

23. Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses

28. Genomics reveal admixture and unexpected patterns of diversity in a parapatric pair of butterflies

31. Reliability of a Seven-Segment Foot Model with Medial and Lateral Midfoot and Forefoot Segments During Walking Gait.

32. Neurological Applications

34. The Effect of Boundary Shape and Minima Selection on Single Limb Stance Postural Stability.

35. Gender Comparisons Between Unilateral and Bilateral Landings.

37. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E

Catalog

Books, media, physical & digital resources